BCMA Targeted Therapies - Competitive landscape, 2026

DelveInsight’s, “BCMA Targeted Therapies - Competitive landscape, 2026” report provides comprehensive insights about 90+ companies and 90+ drugs in BCMA Targeted Therapies Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

BCMA Targeted Therapies: Understanding

BCMA Targeted Therapies: Overview

B-cell maturation antigen (BCMA) has emerged as one of the most actively pursued targets in modern oncology drug development, owing to its restricted expression on plasma cells and its central role in plasma cell survival and proliferation B-cell maturation antigen (BCMA) is a plasma cell surface protein central to the proliferation and survival of malignant plasma cells. This selective expression profile has made BCMA an attractive target for antibody- and cell-based therapeutics, leading to the development of multiple modalities designed to direct immune-mediated killing toward BCMA-expressing cells the major classes explored include chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies that co-engage BCMA and CD3 on T cells, in addition to antibody-drug conjugates.

BCMA-targeted therapies fall into three main classes that are CAR T-cell therapies, bispecific antibodies (BsAbs), and antibody-drug conjugates (ADCs) the three main categories of targeted therapies for BCMA include bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor modified T-cell therapy. CAR-T therapies genetically engineer a patient's own T cells to target BCMA-expressing cells, while BsAbs redirect T cells by simultaneously engaging BCMA and CD3, offering an off-the-shelf option without CAR-T's manufacturing bispecific antibodies provide an off-the-shelf treatment option, especially useful for patients who may not be candidates for CAR-T therapy due to manufacturing time or prior lympho depletion requirements. ADCs instead deliver a cytotoxic payload directly to tumor cells via a BCMA-directed antibody.

B-cell maturation antigen (BCMA), also known as CD269 or TNFRSF17, is a cell-surface protein expressed predominantly on mature B cells and plasma cells and plays an important role in their proliferation, differentiation, and survival. Its restricted expression pattern and presence on plasma cells make BCMA an attractive target for therapeutic development. BCMA-targeted therapies are designed to recognize and eliminate BCMA-expressing cells through different immune-mediated mechanisms. Major therapeutic approaches include chimeric antigen receptor (CAR) T-cell therapies, bispecific T-cell–engaging antibodies, and antibody–drug conjugates (ADCs). CAR-T therapies genetically modify T cells to express a BCMA-directed CAR, enabling them to recognize BCMA-positive cells and induce their destruction, whereas bispecific antibodies simultaneously bind BCMA on the target cell and CD3 on T cells to bring the two cells into close proximity and activate T-cell–mediated cytotoxicity. ADCs use a BCMA-binding antibody to selectively deliver a cytotoxic payload to BCMA-expressing cells. The therapeutic potential of BCMA targeting has driven continued development of these approaches, although challenges such as antigen escape, soluble BCMA, treatment resistance, cytokine release syndrome, and neurotoxicity remain important considerations for improving the safety and durability of BCMA-directed therapies.

BCMA-targeted therapies CAR-T, bispecific antibodies, and ADCs have transformed relapsed/refractory multiple myeloma treatment, delivering deep, durable responses even in heavily pretreated patients B-cell maturation antigen-targeted therapies including CAR T-cell therapies and bispecific antibodies have revolutionized the treatment landscape for relapsed/refractory multiple myeloma, offering deep and durable responses even in heavily pretreated patients. The BCMA therapeutic landscape is advancing through next-generation and dual-targeting therapies, including CAR-T cells and trispecific antibodies, with increasing evaluation in earlier lines of treatment and newly diagnosed disease.

Report Highlights

• In June 2026, Caribou Biosciences reported longer follow up data for the ongoing CaMMouflage phase I trial of CB-011, the Company’s off-the-shelf BCMA-targeted CAR-T cell therapy, being evaluated for relapsed or refractory multiple myeloma (r/r MM).

• In May 2026, Regeneron Pharmaceuticals, Inc. announced positive results from the Phase I/II LINKER-AL2 trial evaluating Lynozyfic (linvoseltamab) in adults with second-line-plus systemic amyloid light chain (AL) amyloidosis, which will be featured in an oral presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting.

• In May 2026, Cartesian Therapeutics, Inc. announced that it has entered into an agreement with K2 HealthVentures LLC (“K2HV”), an alternative investment firm that provides flexible, long-term financing solutions in life sciences, to provide a credit facility of up to USD 150 million including an initial USD 50 million tranche. The proceeds from the initial tranche under the credit facility are expected to allow the Company to accelerate the ongoing investment in the commercial launch preparation activities for Descartes-08 in myasthenia gravis (MG) and myositis and to extend cash runway into 2028.

• In April 2026, Pfizer Inc. announced positive topline results from the Phase III MagnetisMM-5 study evaluating ELREXFIO (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at least one prior line of treatment. The study demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression free survival (PFS), as assessed by blinded independent central review (BICR), versus standard-of-care daratumumab plus pomalidomide and dexamethasone (DPd). The safety and tolerability of ELREXFIO was consistent with its known safety profile.

• In April 2026, Gilead Sciences, Inc. announced the successful completion of its previously announced acquisition of Arcellx, Inc. Under the terms of the transaction, Gilead acquired Arcellx for USD 115 per share in cash, plus one non?transferable contingent value right (CVR) of USD 5 per share, representing a total implied equity value of approximately USD7.8 billion at the time of closing. The acquisition builds on Kite, a Gilead Company, and Arcellx’s successful collaboration and provides Gilead with full control of anitocabtagene autoleucel (anito?cel), an investigational BCMA?directed CAR T?cell therapy for multiple myeloma.

• In March 2026, Keymed Biosciences Inc. announced that its NewCo partner Ouro Medicines has entered into a definitive merger agreement with Gilead Sciences. Gilead will acquire Ouro Medicines for up to USD 2.175 billion, with Keymed set to receive approximately USD 320 million as a shareholder. The transaction accelerates global development of CM336/OM336, a potential best-in-class T-cell engager (TCE) for autoimmune diseases, with tiered royalties now fulfilled by Gilead.

• In March 2026, Caribou Biosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011 for relapsed or refractory multiple myeloma (r/r MM). CB-011, an allogeneic anti-BCMA CAR-T cell therapy, is being evaluated in the company’s ongoing open-label, multicenter CaMMouflage phase I clinical trial evaluating patients with relapsed or refractory multiple myeloma (r/r MM).

• In January 2026, Innovent Biologics, Inc. announced that its anti-GPRC5D/BCMA/CD3 tri-specific antibody IBI3003 has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). This designation applies to the treatment of relapsed or refractory multiple myeloma, (R/R MM) in patients who have received four or more lines of previous anti-myeloma therapies, that include at least a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody.

• In July 2025, Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti?CD38 monoclonal antibody. Lynozyfic was granted accelerated approval based on response rate and durability of response in the LINKER-MM1 trial. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

• In April 2025, Regeneron Pharmaceuticals, Inc. announced that the European Commission (EC) has granted conditional marketing approval of Lynozyfic™ (linvoseltamab) to treat adults with relapsed and refractory (R/R) multiple myeloma (MM). The indication is specific to those who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.

?

BCMA Targeted Therapies: Company and Product Profiles (Marketed Therapies)

1. Company Overview: Regeneron Pharmaceuticals

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, the company’s unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and?product candidates in development, most of which were homegrown in our laboratories. Regeneron?pushes the boundaries of scientific discovery and?accelerates drug development?using?our proprietary technologies, such as VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies.

Product Description: LYNOZYFIC

LYNOZYFIC (linvoseltamab-gcpt) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Lynozyfic is the first FDA-approved BCMAxCD3 bispecific antibody that can be dosed every two weeks starting at week 14, and every four weeks if a very good partial response (VGPR) or better is achieved following completion of at least 24 weeks of therapy. The drug was approved in 2025 to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti?CD38 monoclonal antibody.

2. Company Overview: Pfizer

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology and the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world. In 2021, the company generated net sales of DKK 9,957 million.

Product Description: Elranatamab

Elranatamab is a BCMA-directed and CD3-directed bispecific T-cell engager antibody. According to the FDA label, it binds to B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells, thereby bringing T cells into proximity with BCMA-expressing malignant plasma cells and facilitating T-cell–mediated killing of the tumor cells. It is administered by subcutaneous injection.

BCMA Targeted Therapies: Company and Product Profiles (Pipeline Therapies)

1. Company Overview: Astrazeneca

AstraZeneca is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines across major therapeutic areas, including oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, and rare diseases. The company leverages its capabilities in research and development, biologics, precision medicine, and novel therapeutic modalities to address significant unmet medical needs and advance treatments for patients worldwide.

Product Description: AZD0120

AZD0120 is an investigational autologous dual-targeting chimeric antigen receptor T-cell (CAR-T) therapy, formerly known as GC012F, designed to simultaneously target B-cell maturation antigen (BCMA) and CD19. BCMA is highly expressed on plasma cells, including malignant plasma cells, while CD19 is expressed on B cells and certain plasma-cell populations. AZD0120 genetically engineers a patient’s T cells to express a CAR that recognizes both BCMA- and CD19-expressing cells, thereby activating T-cell signaling and inducing targeted cytotoxicity and elimination of these cells. By simultaneously targeting the two antigens, AZD0120 is intended to provide broader depletion of disease-associated B-cell and plasma-cell populations compared with single-antigen targeting. Currently, the drug is in Phase III of its development for the treatment of relapsed or refractory multiple myeloma.

2. Company Overview: Cartesian Therapeutics

Cartesian Therapeutics is a clinical-stage biotechnology company founded in 2016 and headquartered in Frederick, Maryland, USA, focused on developing innovative cell therapies for autoimmune diseases. The company is pioneering mRNA-engineered cell therapies, using its proprietary RNA-based cell engineering platform to develop treatments designed to selectively target disease-driving immune cells while potentially improving the safety, repeatability, and accessibility of cell therapy.

Product Description: Descartes-08

Descartes-08 is an autologous, BCMA-targeted messenger RNA (mRNA) chimeric antigen receptor T-cell (CAR-T) therapy designed for autoimmune diseases. It uses a patient’s own T cells, which are transiently engineered with mRNA encoding an anti-BCMA CAR, enabling the T cells to recognize and eliminate BCMA-expressing pathogenic plasma cells, plasmablasts, and plasmacytoid dendritic cells. By selectively depleting these BCMA-positive cell populations, Descartes-08 is intended to reduce the production of disease-causing autoantibodies and inflammatory signaling, thereby producing a targeted immune reset while preserving broader protective B-cell and immune function. Unlike conventional integrating CAR-T approaches, its mRNA-based CAR expression is transient, allowing temporary targeting of pathogenic cells without genomic integration. Currently, the drug is in Phase III of its development for the treatment of Myasthaenia Gravis.

?

3. Company Overview: Caribou Biosciences

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing transformative, genome-edited allogeneic cell therapies for patients with serious diseases. The company has developed a proprietary next-generation CRISPR hybrid RNA-DNA (chRDNA) technology, which is designed to improve genome-editing specificity and enable efficient, multiplexed editing while maintaining genomic integrity. Caribou applies this technology to develop off-the-shelf CAR-T cell therapies, with its current pipeline focused primarily on hematologic malignancies. The company’s approach also incorporates “armoring” strategies, such as immune cloaking and checkpoint disruption, intended to enhance the activity and persistence of its cell therapies.

Product Description: CB-011

CB-011 is an allogeneic anti-BCMA CAR-T cell therapy being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM). To the company’s knowledge, CB-011 is the first allogeneic CAR-T cell therapy in the clinic that is engineered to enable activity through an immune cloaking strategy with a B2M knockout and insertion of a B2M–HLA-E-peptide fusion protein to blunt immune-mediated rejection. The FDA granted CB-011 RMAT, Fast Track, and Orphan Drug designations for relapsed or refractory multiple myeloma (r/r MM). Currently, the drug is in Phase I of its development for the treatment of relapsed or refractory multiple myeloma.

4. Company Overview: CSPC Zhongqi Pharmaceutical Technology

CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. is a China-based pharmaceutical research and Development Company and a wholly owned subsidiary of CSPC Pharmaceutical Group Limited. The company was established in 2003 and is headquartered in Shijiazhuang, Hebei, China, with its core activities focused on pharmaceutical research and development, new drug and pharmaceutical technology development, technology transfer, and related technical services. CSPC Zhongqi operates as part of CSPC Pharmaceutical Group’s broader R&D network, supporting the development of innovative and complex pharmaceutical products and proprietary technologies.

Product Description: SYS6020

SYS6020 is an autologous B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy manufactured using an mRNA–lipid nanoparticle (LNP)-based transfection approach. The therapy transiently equips a patient’s own T cells with a CAR capable of specifically recognizing BCMA, which is expressed on plasma cells and pathogenic BCMA-positive B-cell populations. Upon recognition of BCMA-expressing cells, SYS6020 activates the engineered T cells and induces targeted cytotoxicity, resulting in the elimination of these cells. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Refractory Active Systemic Lupus Erythematosus and Myasthenia Gravis.

5. Company Overview: Sana Biotechnology

Sana Biotechnology, Inc. is a clinical-stage biotechnology company founded in July 2018 and headquartered in Seattle, Washington, USA, with additional operations in Cambridge, Massachusetts, and South San Francisco, California. The company focuses on developing engineered cell therapies designed to address the underlying causes of disease by repairing or controlling genes within cells and replacing missing or damaged cells. Sana combines technologies across cell engineering, gene therapy, gene editing, stem cell biology, and immunology to develop potentially transformative medicines for diseases with significant unmet medical needs.

Product Description: SG227

SG227 is a CD8-targeted fusosome designed to deliver genetic material directly to CD8+ T cells, enabling them to become BCMA-directed CAR T cells. The fusosome targets CD8+ T cells and delivers the genetic payload encoding a BCMA-directed chimeric antigen receptor (CAR); the resulting CAR T cells are intended to recognize and target BCMA-expressing myeloma cells, thereby enabling an in vivo CAR T-cell approach for multiple myeloma. Currently, the drug is being evaluated in the Preclinical stage of its development.

Further product details are provided in the report……..

BCMA Targeted Therapies Analytical Perspective by DelveInsight

• In-depth Commercial Assessment: BCMA Targeted Therapies Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

• BCMA Targeted Therapies Competitive Landscape

The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

BCMA Targeted Therapies Report Assessment

• Company Analysis
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing BCMA Targeted Therapies drugs?
• How many BCMA Targeted Therapies drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of BCMA Targeted Therapies?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the BCMA Targeted Therapies therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for BCMA Targeted Therapies and their status?
• What are the key designations that have been granted to the emerging and approved drugs?

Key Players

• Regeneron Pharmaceuticals
• Pfizer
• AstraZeneca
• Cartesian Therapeutics
• Caribou Biosciences
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Sana Biotechnology
• iCell Gene Therapeutics
• Qilu Pharmaceutical
• UCB Biopharma
• Gilead Sciences
• AbelZeta Pharma
• Nexcella Inc.
• Johnson & Johnson
• Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
• Umoja Biopharma

Key Products

• LYNOZYFIC
• Elranatamab
• AZD0120
• Descartes-08
• CB-011
• SYS6020
• SG227
• CM336
• QLS4131
• Cizutamig
• Anito-cel
• C-CAR168
• NXC-201
• ISB 2001
• Ramantamig
• HDP-101
• UB-VV500